吉林敖东：打造特色中医药产业强基之路

Core Viewpoint - The traditional Chinese medicine industry is currently in a significant development opportunity period, and the company aims to leverage policy and market opportunities to innovate and grow within this sector [1] Group 1: Strengthening Traditional Chinese Medicine Industry - The company originated from a state-owned deer farm and has established a standardized breeding base for Sika deer, ensuring high-quality raw materials for traditional Chinese medicine [1][2] - The company has invested over 46 million yuan in upgrading epidemic prevention facilities, maintaining a zero-positive record for brucellosis and tuberculosis since 2021 [1][2] - The company has obtained 525 registration certificates in the Chinese medicine granule sector, enhancing its influence in industry standards [2] Group 2: Research and Development Innovation - The company focuses on core material research and has increased investment in technology development, transitioning from experience-based practices to scientific decoding [2][4] - The company has developed a product cluster centered around Sika deer, including various medicinal products, creating an ecological closed loop from breeding to pharmaceutical products [2][3] - The company emphasizes the integration of research, breeding, processing, and market feedback to drive fundamental changes in production methods [4] Group 3: Financial and Capital Interaction - The company has adopted a dual-driven development model of "healthcare + financial capital," using financial resources to support long-term research and development [5][6] - The company is the largest shareholder of Guangfa Securities, which has provided significant cash flow and stability, contributing 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024, respectively [6] - The company collaborates with various universities and research institutions to enhance its research capabilities and invest in promising biopharmaceutical projects [6][7]